Browse > Home / FDA News / FDA has approved expanded indications for the use of Isentress

FDA has approved expanded indications for the use of Isentress

July 14, 2009

isentressOffice of foodstuffs and medicines USA (Food and Drug Administration - FDA) has approved expanded indications for use of the drug Isentress ® (raltegravir, «Merck & Co.») In combination with other antiretrovirals in patients with HIV have not previously received treatment. The new indication for use could help to increase sales volumes of the drug, which in 2009, according to analysts from the «JP Morgan», will grow to approximately 700 million USD. United States, compared with 360 million USD. last year - reported July 10, German edition «FinanzNachrichten».

The drug Isentress received accelerated approval from the FDA in October 2007 in combination with other antiretroviral drugs for the treatment of adult patients with HIV-1, which, despite ongoing therapy, other anti-retroviral drugs, observed replication of the virus.

Written by Samanta · Filed Under FDA News